United States Senate

The United States Senate entered the book’s account of psychedelic research at a moment when the scientific enterprise was under mounting political pressure. Its May 1966 hearings on LSD brought the dispute over medical research and illicit use into a public congressional forum. The hearings are presented not as a resolution of that dispute, but as a brief opening in which defenders of research could make their case before the government moved toward broader restrictions.

The May 1966 hearings

Timothy Leary and Sidney Cohen both testified, attempting to defend psychedelic research while distinguishing legitimate use from the black market the government was determined to crush. Their joint appearance placed two researchers with different positions in the field before the same legislative audience, making the hearing a public test of whether research could still be separated from the drug’s widening controversy.

Senator Robert F. Kennedy proved a notably sympathetic listener. The account connects that sympathy, reportedly, to his wife Ethel’s prior LSD treatment at Hollywood Hospital in Vancouver. Kennedy challenged Food and Drug Administration regulators over plans to cancel remaining research projects, asking why projects considered worthwhile six months earlier should no longer be so. He warned that excluding psychedelics from medicine because of illicit use would be a loss to the nation, and argued that, when properly used, they could help society.

Research, medicine, and illicit use

The hearing exposed a fault line that extended beyond whether LSD should be available. The issue was whether a drug associated with illicit use could still be treated as a legitimate instrument of medical research. Leary and Cohen tried to preserve that distinction in their testimony; Kennedy pressed regulators to account for the change in policy toward projects that had recently been approved. In this account, the Senate served as a forum for contesting the boundary between therapeutic use and a black market, rather than as a body that settled the scientific questions at stake.

That dispute had become harder to contain as psychedelic therapy itself challenged familiar professional categories. Its advocates described a treatment centered on a high-dose session and a conversion-like experience, while critics objected to the spiritual dimensions and to researchers’ involvement with the drugs they studied. The Senate hearing formed part of this wider struggle over the credibility and legitimacy of psychedelic research, but the available account does not show the chamber resolving those deeper conflicts.

Limits and aftermath

Kennedy’s support did not change the outcome. In October 1966, the Food and Drug Administration sent letters ordering roughly sixty psychedelic researchers across the country to stop their work. The account records Kennedy’s appeal and the testimony of Leary and Cohen, but it does not attribute the subsequent shutdown to a Senate decision. Rather, the hearing’s sympathetic response proved insufficient to protect research from the regulatory action that followed.

The Senate’s significance here is therefore sharply bounded: it gave defenders of research a public hearing at the moment when distinctions between medical use and illicit use were collapsing in political debate, and it included a forceful challenge to regulators from Kennedy. Yet the episode also registers the limits of that intervention. A sympathetic question in Congress could make the stakes visible without preserving the research programs that were soon ordered to close.